Guardant Health, Inc. - Common Stock (NQ:GH)

93.83 +2.68 (+2.94%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,744,127
Open	87.67
Bid (Size)	87.00 (2,100)
Ask (Size)	94.00 (300)
Prev. Close	91.15
Today's Range	86.42 - 94.02
52wk Range	36.36 - 120.74
Shares Outstanding	101,298,669
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

Today 0:32 EDT

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...

Via StockStory

Why Is Guardant Health (GH) Stock Soaring Today

March 31, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.9% in the afternoon session after the company announced that real-world evi...

Via StockStory

Performance

YTD	-7.8%	-7.8%
1 Month	+1.7%	+1.7%
3 Month	-8.1%	-8.1%
6 Month	+49.8%	+49.8%
1 Year	+120.9%	+120.9%

More News

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

March 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗

February 19, 2026

Via Chartmill

Why Guardant Health (GH) Stock Is Falling Today

March 27, 2026

Via StockStory

3 Growth Stocks We Think Twice About

March 26, 2026

Via StockStory

Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics

March 23, 2026

Via MarketMinute

3 Reasons to Avoid GH and 1 Stock to Buy Instead

March 19, 2026

Via StockStory

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

March 18, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

March 16, 2026

From Guardant Health, Inc.

Via Business Wire

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

Via The Motley Fool

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

March 13, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

March 10, 2026

From Guardant Health, Inc.

Via Business Wire

1 Russell 2000 Stock on Our Watchlist and 2 We Question

March 05, 2026

Via StockStory

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

March 04, 2026

From Guardant Health, Inc.

Via Business Wire

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

March 03, 2026

From Guardant Health, Inc.

Via Business Wire

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

February 27, 2026

Via StockStory

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2026

From Guardant Health, Inc.

Via Business Wire

The Great Rotation: Small-Caps Break Record Highs as the 'Catch-Up' Trade Ignites

February 26, 2026

Via MarketMinute

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

February 23, 2026

Via StockStory

Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

February 19, 2026

Via StockStory

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

February 19, 2026

From Guardant Health, Inc.

Via Business Wire

Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow

February 17, 2026

Via StockStory

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?

Yes, Guardant Health, Inc. - Common Stock is publicly traded.

What exchange does Guardant Health, Inc. - Common Stock trade on?

Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Guardant Health, Inc. - Common Stock?

The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market

What is the current price of Guardant Health, Inc. - Common Stock?

The current price of Guardant Health, Inc. - Common Stock is 93.83

When was Guardant Health, Inc. - Common Stock last traded?

The last trade of Guardant Health, Inc. - Common Stock was at 04/02/26 04:00 PM ET

What is the market capitalization of Guardant Health, Inc. - Common Stock?

The market capitalization of Guardant Health, Inc. - Common Stock is 9.50B

How many shares of Guardant Health, Inc. - Common Stock are outstanding?

Guardant Health, Inc. - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.